Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD39 high-affinity antibody and use thereof

A CDR-H3, CDR-L3 technology, applied in the direction of antibodies, applications, anti-tumor drugs, etc., can solve the problem of loss of inhibitory function

Active Publication Date: 2019-11-05
EPIMAB BIOTHERAPEUTICS INC
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Furthermore, Tregs from CD39 knockout mice are constitutively activated, hyperproliferate, and lose their suppressive function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD39 high-affinity antibody and use thereof
  • CD39 high-affinity antibody and use thereof
  • CD39 high-affinity antibody and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0133] Example 1: Production of anti-CD39 monoclonal antibodies

[0134] Mouse anti-human CD39 and rat anti-mouse CD39 monoclonal antibodies were obtained as follows.

Embodiment 11

[0135] Example 1.1(a): Immunization of mice with human CD39 antigen

[0136] 50 μg of recombinant purified human CD39 protein (R&D Systems, Inc., Minneapolis, MN, USA) mixed with complete Freund’s adjuvant, or 5×10 without adjuvant 6 Cells of the CHO-K1-human CD39 stable cell line were injected intraperitoneally on day 1 into two groups of five 6-8 week-old Balb / C and SJL mice. On days 14 and 35, 25 micrograms of recombinant purified human CD39 protein mixed with incomplete Freund's adjuvant, or 5×10 without adjuvant 6 The CHO-K1-human CD39 stable cell line was injected intraperitoneally into the same mice. A final boost with the same immunogen was performed 3-4 days prior to fusion.

Embodiment 11

[0137] Example 1.1(b): Immunization of rats with mouse CD39 antigen

[0138] On day 1, 100 μg of recombinant purified mouse CD39 protein (Chempartner Co., Ltd.; Shanghai) mixed with complete Freund's adjuvant was intraperitoneally injected into a 6-8 week old Sprague Dawley rat. On days 14 and 35, 50 μg of recombinant purified mouse CD39 protein mixed with incomplete Freund's adjuvant was injected intraperitoneally into the same rats. A final boost with the same immunogen was performed 3-4 days prior to fusion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a high-affinity antibody that identifies CD39. The antibody is capable of neutralizing the ATPase activity of CD39 on cells expressing CD39. The antibody can be used for the treatment of cancer and other diseases mediated by CD39 activity.

Description

technical field [0001] The present invention relates to a novel antibody recognizing CD39, which is also called ectonucleoside triphosphate diphosphohydrolase-1 or NTPDase 1. CD39 antibodies can be used to treat immune diseases and cancer. Background technique [0002] A hallmark of cancer cells is their ability to evade immune-mediated destruction through the acquired expression of multiple negative regulators of the immune response. Such negative regulators, now often referred to as "immune checkpoints," include surface receptors such as CTLA-4 (CD152) and PD-L1 (CD274). Targeting these key regulators of the immune response has emerged as a new therapeutic option to prevent tumor-mediated immunosuppression and establish long-lasting cancer-specific immune responses. Bonnefoy et al., OncoImmunology , 4:5, e1003015 (2015). Antibody-mediated blockade of these immunomodulatory pathways has led to promising clinical outcomes. However, since objective responses are observed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/40C07K16/28C12N15/13C12P21/02A61K39/395A61P35/00
CPCC07K16/40C07K16/2896A61P35/00C07K2317/23C07K2317/33C07K2317/92C07K2317/56C07K2317/565A61K2039/505C07K2317/24C07K2317/76C07K2317/567C07K2317/73
Inventor 任芳宫世勇吴辰冰
Owner EPIMAB BIOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com